Gabapentin
Product Images NDC 42495-266

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 42495-266). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Msm Repackaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (9e722109 1eef 40c2 8e93 46ef9fb42029 01)

Chemical structure of gabapentin, showing a cyclohexane ring attached to a central carbon connected to an amino-methyl group and a carboxymethyl group.*

FDA Label Image

Image Description (9e722109 1eef 40c2 8e93 46ef9fb42029 02)

A line graph depicting weekly mean pain scores over an 8-week period, comparing placebo and gabapentin 3600 mg/day groups. The x-axis shows weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis represents mean pain scores from 0 to 10. Gabapentin shows a decreasing trend in pain score, significantly lower than placebo at several points.*

FDA Label Image

Image Description (9e722109 1eef 40c2 8e93 46ef9fb42029 03)

A line graph showing weekly mean pain scores over seven weeks for Gabapentin at 1800 mg/day and 2400 mg/day compared to placebo. The x-axis represents weeks including a 3-week dose titration and 4-week fixed dose period, and the y-axis shows mean pain scores from 0 to 10. Gabapentin groups show lower mean pain scores than placebo, with statistical significance (p < 0.01) marked during treatment weeks.*

FDA Label Image

Image Description (Equation)

A formula for calculating Creatinine Clearance (CLCr) based on patient age in years, weight in kilograms, serum creatinine in mg/dL, and a gender adjustment factor of 0.85 for female patients. The equation is presented in a mathematical format showing the relationship among these variables.*

FDA Label Image

Image Description (Gaba 05)

A bar graph titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing data from two studies. Study 1 compares placebo (PBO) at 12% with Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo at 14%, GBP 1800 mg at 32%, and GBP 2400 mg at 34%. Statistical significance is indicated with p-values below 0.01 and 0.001.*

FDA Label Image

Figure 4 (Gaba 06)

A scatter plot showing the percentage difference on the y-axis against daily dose in mg on the x-axis for Gabapentin. Data points are labeled as studies a, b, and c, represented by different colored squares, illustrating the variation in difference percentages across daily doses of 600, 900, 1200, and 1800 mg.*

FDA Label Image

Image Description (Snip Gab 42495 266 30)

Label for Gabapentin 300 mg capsules, 30 count. The label indicates Rx only and includes a barcode, manufacturer as Solco Healthcare US, LLC, and repackaging by MSM Repackaging located in Richmond, VA. The label mentions usual dosage and storage conditions to see insert, with placeholders for lot number, ID, and expiration date.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.